Cited by 69

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

A new framework for advancing in drug‐induced liver injury research. The Prospective European DILI Registry

Björnsson, Einar S., Stephens, Camilla, Atallah, Edmond, Robles‐Diaz, Mercedes, Alvarez‐Alvarez, Ismael, Gerbes, Alexander, Weber, Sabine, Stirnimann, Guido, Kullak‐Ublick, Gerd, Cortez‐Pinto, Helena, Grove, Jane I., Lucena, M. Isabel, Andrade, Raul J., Aithal, Guruprasad P.·2023·Liver International

Abstract

Background & Aims: No multi‐national prospective study of drug‐induced liver injury (DILI) has originated in Europe. The design of a prospective European DILI registry, clinical features and short‐term outcomes of the cases and controls is reported. Methods: Patients with suspected DILI were prospectively enrolled in the United Kingdom, Spain, Germany, Switzerland, Portugal and Iceland, 2016–2021. DILI cases or non‐DILI acute liver injury controls following causality assessment were enrolled. Results: Of 446 adjudicated patients, 246 DILI patients and 100 had acute liver injury due to other aetiologies, mostly autoimmune hepatitis ( n = 42) and viral hepatitis ( n = 34). DILI patients (mean age 56 years), 57% women, 60% with jaundice and 3.6% had pre‐existing liver disease. DILI cases and non‐DILI acute liver injury controls had similar demographics, clinical features and outcomes. A single agent was implicated in 199 (81%) DILI cases. Amoxicillin‐clavulanate, flucloxacillin, atorvastatin, nivolumab/ipilimumab, infliximab and nitrofurantoin were the most commonly implicated drugs. Multiple conventional medications were implicated in 37 (15%) and 18 cases were caused by herbal and dietary supplements. The most common single causative drug classes were antibacterials (40%) and antineoplastic/immunomodulating agents (27%). Overall, 13 (5.3%) had drug‐induced autoimmune‐like hepatitis due to nitrofurantoin, methyldopa, infliximab, methylprednisolone and minocycline. Only six (2.4%) DILI patients died (50% had liver‐related death), and another six received liver transplantation. Conclusions: In this first multi‐national European prospective DILI Registry study, antibacterials were the most commonly implicated medications, whereas antineoplastic and immunomodulating agents accounted for higher proportion of DILI than previously described. This European initiative provides an important opportunity to advance the study on DILI.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/liv.15378

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Expert judgement is the approach used to assess causality in large prospective DILI registries such as the Spanish, Latin American, European, and DILIN registries.

    “Expert judgement is the approach used to assess causality in large prospective DILI registries such as the Spanish, the Latin American, the European, or the DILIN.”
  • In response to limitations of expert judgement, the Spanish, LATINDILI and Pro-Euro DILI networks combined evaluation of suspected DILI cases by three experts with further assessment using causality scales, while DILIN developed a structured expert opinion process.

    “In response to these limitations, the Spanish, LATINDILI and Pro‐Euro DILI networks have combined the evaluation of suspected DILI cases by three experts and further assessment using causality scales, while the DILIN has developed a structured expert opinion process.”
  • The pharmacological groups most frequently involved in DILI are antimicrobials, cardiovascular system drugs, and musculoskeletal system drugs, although this varies according to country and areas of the world.

    “The pharmacological groups most frequently involved in DILI are antimicrobials, cardiovascular system drugs, and musculoskeletal system drugs, although this varies according to country and areas of the world [3][4][5][6].”
  • ChILI is accounting for an increasing proportion of recent DILI cohort studies.

    “Checkpoint inhibitor-induced liver injury (ChILI) is accounting for an increasing proportion of recent DILI cohort studies.”
  • There are differences between the main agents responsible in the three registries analysed.

    “It is important to note that there are differences between the main agents responsible in the three registries analysed (Table 1; Fig. 1) [3][4][5].”

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Flagged first, then by citations

Research works printed but not linked: 36

  1. 10.1016/j.dld.2005.06.004 · DOI
  2. 10.1016/j.jhep.2021.01.029 · DOI
  3. 10.1002/hep.20800 · DOI · Paper page
  4. 10.1097/MEG.0000000000002272 · DOI
  5. 10.1053/j.gastro.2015.03.006 · DOI · Paper page
  6. 10.1016/j.jceh.2020.11.002 · DOI
  7. 10.1038/ajg.2012.138 · DOI
  8. 10.1016/S0140-6736(21)01701-3 · DOI · Paper page
  9. 10.1038/clpt.2011.58 · DOI
  10. 10.1053/j.gastro.2014.03.050 · DOI · Paper page
  11. 10.1016/0895-4356(93)90101-6 · DOI · Paper page
  12. 10.1038/ajg.2015.283 · DOI
  13. Chijioke O, 2015, Hepatitis E virus detection in liver tissue from patients with suspected drug‐induced liver injury, Front Med (Lausanne), 2, 20
  14. 10.1111/liv.14713 · DOI
  15. 10.3389/fmicb.2021.737486 · DOI
  16. 10.1053/j.gastro.2008.09.011 · DOI
  17. 10.1016/j.jhep.2018.01.033 · DOI · Paper page
  18. 10.1111/liv.13746 · DOI · Paper page
  19. 10.14309/ajg.0000000000000398 · DOI
  20. 10.1002/hep.28323 · DOI · Paper page
  21. 10.1016/j.cgh.2012.12.025 · DOI
  22. 10.1016/j.cgh.2014.07.062 · DOI · Paper page
  23. 10.1016/j.jhep.2021.08.024 · DOI · Paper page
  24. 10.1111/j.1365-2125.2004.02133.x · DOI
  25. 10.1111/bcp.14254 · DOI
  26. 10.1111/bcp.14294 · DOI
  27. 10.1007/s40264-021-01049-z · DOI
  28. 10.1016/j.jhep.2011.07.023 · DOI
  29. 10.1371/journal.pone.0151587 · DOI
  30. 10.4414/smw.2021.20503 · DOI · Paper page
  31. 10.1002/hep.23588 · DOI · Paper page
  32. 10.1016/j.cgh.2016.05.043 · DOI · Paper page
  33. 10.3389/fphar.2021.744488 · DOI
  34. 10.3389/fphar.2022.876868 · DOI
  35. 10.3389/fphar.2022.820724 · DOI
  36. 10.1016/j.phrs.2020.105404 · DOI · Paper page

Cited by

Sorted by citations

Metadata

Authors
Björnsson, E. S., Stephens, C., Atallah, E., Robles‐Diaz, M., Alvarez‐Alvarez, I., Gerbes, A., Weber, S., Stirnimann, G., Kullak‐Ublick, G., Cortez‐Pinto, H., Grove, J. I., Lucena, M. I., Andrade, R. J., & Aithal, G. P.
Affiliations
  • Faculty of Medicine University of Iceland Reykjavík Iceland
  • Servicios de Aparato Digestivo y Farmacología Clínica Hospital Universitario Virgen de la Victoria, Instituto de Investigación Biomédica de Málaga y Plataforma en Nanomedicina‐IBIMA Plataforma BIONAND, Universidad de Málaga Málaga Spain
  • Nottingham Digestive Diseases Centre, Translational Medical Sciences, School of Medicine University of Nottingham Nottingham UK
  • Department of Medicine II LMU Klinikum Munich Munich Germany
  • Department of Visceral Surgery and Medicine Inselspital University Hospital and University of Bern Bern Switzerland
  • Department of Clinical Pharmacology and Toxicology University Hospital Zurich, University of Zurich Zurich Switzerland
  • Clínica Universitária de Gastrenterologia, Faculdade de Medicina de Lisboa Universidade de Lisboa, Centro Hospitalar Lisboa Norte, HSM Lisbon Portugal
Venue
Liver International
Publisher
Wiley
Published
2022-08-15
Volume
43
Issue
1
Pages
115-126
ISSN
  • 1478-3223
  • 1478-3231
Cited by
69
References
7
Language
en
Funders
  • Agencia Española de Medicamentos y Productos Sanitarios
  • Instituto de Salud Carlos III
  • European Cooperation in Science and Technology

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review